Delaware
|
000-21429
|
04-3221586
|
||||||||
(State or other jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
||||||||
of incorporation)
|
Identification No.)
|
19 Presidential Way
|
||||
Woburn, MA
|
||||
(Address of principal executive offices) |
01801
|
||||
(Zip code) |
(781) 994-0300
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 8 — Other Events
Item 8.01 Other Events.
On November 10, 2014, ArQule, Inc. (the “Registrant”) issued a press release announcing the top-line results of a single agent trial of tivantinib sponsored by the National Cancer Institute (NCI) in metastatic prostate cancer. The press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
2 |
ARQULE, INC.
|
|||
(Registrant) | |||
/s/ Peter S. Lawrence | |||
Peter S. Lawrence
|
|||
President and Chief Operating Officer
|
|||
3 |